20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in normal renal function
HD                     :Not dialysed. Dose as in normal renal function
HDF/high flux   :Unknown dialysability. Dose as in normal renal function
CAV/VVHD      :Unknown dialysability. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAnaesthetics: enhanced hypotensive effect Analgesics: NSAIDs antagonise hypotensive effectAnti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodaroneAntidepressants: enhanced hypotensive effect with MAOIsAntihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosinAntimalarials: increased risk of bradycardia with mefloquineAntipsychotics: enhanced hypotensive effect with phenothiazinesCalcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamilDiuretics: enhanced hypotensive effect Moxisylyte: possible severe postural hypotensionSympathomimetics: severe hypertension with adrenaline and noradrenaline, and possibly with dobutamine
ADMINISTRATION
Reconstition
–
Route
Topically
Rate of Administration
–
Comments
–
OTHER INFORMATION
Use with caution in patients with asthma, or a history of obstructive airways disease or diabetesSystemic absorption may follow topical administration to the eyeBetaxolol hydrochloride